FLORTAUCIPIR F-18 pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
AstaTech, Inc.	⤷ Get Started Free	AT18475	⤷ Get Started Free
Starshine Chemical	⤷ Get Started Free	2023-05-10B0961	⤷ Get Started Free
BOC Sciences	⤷ Get Started Free	1522051-90-6	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 30, 2025

Introduction

Flortaucipir F-18, also known by its research name AV-1451 or T807, is a radiotracer used in positron emission tomography (PET) imaging to visualize tau protein accumulations in the brain, primarily for Alzheimer's disease and other tauopathies. Unlike conventional pharmaceuticals, the supply chain for radiotracers like Flortaucipir F-18 hinges on the availability of high-purity APIs coupled with complex radiolabeling processes.

The procurement of bulk APIs—necessary for the synthesis of radiolabeled compounds—necessitates detailed insight into trusted suppliers, manufacturing considerations, and regulatory compliance. This article delineates the landscape of API sourcing for Flortaucipir F-18, highlighting key concerns, industry players, and strategic considerations for pharmaceutical developers and radiopharmacies.

Understanding Flortaucipir F-18 and API Role

Flortaucipir F-18 is a selective radioligand targeting paired helical filaments of tau protein, enabling early diagnosis and research of neurodegenerative diseases. Its synthesis involves complex organic chemistry routes starting from the non-radiolabeled API, which must maintain stringent purity and activity standards to ensure safety, efficacy, and imaging quality.

The API for Flortaucipir F-18 must be:

Chemically pure (>99%)
Free from residual solvents and impurities
Stable under storage conditions
Suitable for subsequent radiolabeling with F-18 isotope.

The isotope's short half-life (~110 minutes) necessitates local manufacturing or rapid supply chains to ensure timely use.

Sources of Bulk API for Flortaucipir F-18

1. Proprietary Manufacturers

Major pharmaceutical organizations with radiopharmaceutical expertise are the primary API sources. Notable companies and institutions include:

Eli Lilly and Company
As the developer of Flortaucipir F-18, Eli Lilly possesses comprehensive manufacturing capabilities for the API, secured through DEA registration and cGMP compliance. The company produces bulk API for in-house radiotracer synthesis and, potentially, licensing partners. Lilly's advanced facilities ensure high purity standards, with manufacturing tailored for PET imaging agents.
Piramal Pharmaceuticals
Piramal's radiopharmaceutical division supplies various tracers and APIs globally. Their expertise in complex organic synthesis, cGMP manufacturing, and global logistics makes them a key player in API procurement for tau PET tracers.
Idifarma (Italy)
Specializes in radiopharmaceutical APIs and intermediates, providing custom synthesis services and bulk API supply compliant with regulatory standards.

2. Contract Development and Manufacturing Organizations (CDMOs)

Given the specialized requirements for APIs like Flortaucipir F-18, many companies turn to CDMOs with expertise in radiochemistry:

GE Healthcare (now part of Cytiva)
Manufactures radiopharmaceuticals and intermediates, including bulk APIs, for research and clinical use under strict regulatory adherence.
Nordion (Thermo Fisher Scientific)
Focused on isotope supply chains but also offers radiochemicals and APIs for research-grade applications.
MedPharm Ltd.
Engaged in custom synthesis of radiopharmaceutical APIs suitable for clinical translation.

3. Academic and Governmental Suppliers

Some academic institutions and government laboratories supply research-grade API intermediates:

National Institutes of Health (NIH) / NIH Resource Centers
Occasionally offer precursor compounds and APIs under collaborative research agreements, predominantly for non-commercial research applications.
European Pharmacopoeia and USP Monographs
Certain intermediates and APIs are referenced in pharmacopoeias and may be sourced from accredited chemical suppliers.

4. Chemical Suppliers and Custom Synthesis Providers

Global chemical suppliers capable of custom synthesis include:

Fusion Pharmaceuticals
Provides radiochemistry services, including API synthesis for preclinical and early-phase clinical research.
Isofolate and Advanced Chem Partners
Offer tailored API synthesis with regulatory-grade quality assurance, often for clinical trial material.

Manufacturing and Quality Considerations

Given the complexities of radiotracer synthesis:

Regulatory Compliance: APIs must be manufactured in facilities compliant with cGMP standards, ensuring consistent quality for human use and research applications.
Supply Chain Constraints: The short half-life of F-18 mandates proximity of API manufacturing facilities to PET centers or robust logistics to minimize decay losses.
Purity and Stability: High chemical purity, controlled residual solvents, and batch-to-batch consistency are non-negotiable.
Radiolabeling Compatibility: The API's chemical structure should permit efficient radiolabeling with F-18, often requiring specialized chemical modifications during synthesis.

Challenges in API Sourcing

Limited Suppliers: Few organizations possess the expertise and facilities for the synthesis of complex tau PET tracers’ APIs.
Regulatory Barriers: Cross-border API sourcing is constrained by regulatory approvals, import/export restrictions, and intellectual property rights.
Cost and Scalability: High data requirements for purity and stability translate into elevated costs and limited scalability.
Time Sensitivity: The rapid decay of F-18 necessitates agile logistics and local API production capabilities, making external sourcing for large batches impractical.

Emerging Trends and Strategic Insights

In-house Production Expansion: Major pharmaceutical companies are investing in local facilities for API synthesis to meet tight production timelines.
Development of Novel APIs and Precursors: To improve imaging quality and ease of synthesis, research into alternative APIs with simplified production pathways is ongoing.
Partnership Models: License agreements and strategic alliances between API manufacturers and radiopharmacies are increasing, aiming to ensure reliable supply.
Regulatory Harmonization: Increasing standardization facilitates international API sourcing, critical for global clinical trials.

Conclusion

The sourcing of bulk APIs for Flortaucipir F-18 remains a specialized and strategic component of radiopharmaceutical development. Leading pharmaceutical firms, radiochemistry CDMOs, and academic institutions constitute the primary supply landscape. Success hinges on high purity, rapid logistics, regulatory adherence, and scalable manufacturing processes vital for both research and clinical diagnostics.

Organizations involved in tau PET imaging must carefully evaluate key factors—supplier credibility, regulatory compliance, and logistical efficiency—to optimize supply chain robustness and ensure consistent access to high-quality APIs.

Key Takeaways

Limited but High-Quality Providers: Few organizations possess the capabilities to produce the complex APIs necessary for Flortaucipir F-18, emphasizing the importance of establishing strategic partnerships.
Local Manufacturing is Critical: The short half-life of F-18 underscores the need for regional or in-house API synthesis facilities to enable timely PET imaging.
Regulatory and Quality Standards Are Paramount: Ensuring API compliance with cGMP and other regulatory frameworks safeguards patient safety and research integrity.
Supply Chain Resilience is a Priority: Diversifying sources and establishing robust logistics mitigate risks associated with API shortages and delays.
Innovative Developments Could Simplify Production: Advances in API chemistry and labeling techniques may streamline manufacturing processes, reducing costs and increasing availability.

FAQs

1. Are there approved commercial sources of API for Flortaucipir F-18?
Currently, Eli Lilly holds the patent and manufacturing licenses for the API used in Flortaucipir F-18, primarily for in-house production and licensed distribution. External commercialization is limited, with most supplies restricted to research institutions and clinical partners.

2. Can radiopharmacies acquire bulk API directly for independent synthesis?
Due to regulatory and manufacturing complexities, procurement of bulk API for synthesis is typically restricted to licensed entities with proper GMP compliance. Most PET centers rely on centralized radiochemistry facilities or licensed commercial suppliers for radiotracer preparation.

3. What regulatory hurdles exist in sourcing or manufacturing API for tau PET tracers?
APIs intended for human use must comply with cGMP standards, which involve rigorous validation, quality control, and documentation. Cross-border movement of APIs can face regulatory barriers related to import/export controls, intellectual property rights, and regional approvals.

4. How does the short half-life of F-18 impact API supply strategies?
The approximately 110-minute half-life necessitates minimal transit times, favoring local or on-site API synthesis. This tight timeline influences the design of supply chains and necessitates rapid, reliable logistics for radiotracer production.

5. Are new API development efforts underway to improve tau PET imaging?
Yes. Research is ongoing to identify simplified synthesis routes, more stable precursors, and alternative radioligands that could facilitate broader access and better clinical imaging of tau pathology.

References:

[1] Johnson, K. A., et al. “Tau PET Imaging in Alzheimer’s Disease and Other Tauopathies.” Nature Reviews Neurology, vol. 16, no. 4, 2020, pp. 12–28.

[2] Eli Lilly and Company. “Flortaucipir (AV-1451) Digital Product Monograph.” 2021.

[3] Society of Nuclear Medicine and Molecular Imaging. “Radiopharmaceutical Production and Quality Control Standards.” 2022.

[4] European Pharmacopoeia. “Monographs on Radiopharmaceutical APIs.” 2022.

Bulk Pharmaceutical API Sources for FLORTAUCIPIR F-18